What's Going On With Moderna Stock On Monday?
Portfolio Pulse from Vandana Singh
Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) are collaborating on a new clinical trial for V940, an individualized neoantigen therapy, combined with pembrolizumab for treating advanced cutaneous squamous cell carcinoma. The Phase 2 trial will evaluate the safety and efficacy of this combination compared to standard care. The trial is expected to start next month and conclude by 2029. Analysts from Jefferies and RBC Capital have expressed positive views on this development, highlighting the potential of the therapy and the growing incidence of cSCC. MRNA shares rose 8.96% to $112.26.

March 11, 2024 | 6:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck & Co Inc is collaborating with Moderna on a new trial for V940 combined with pembrolizumab for advanced skin cancer, indicating a strong partnership and investment in innovative therapies.
The collaboration on a new trial for an innovative therapy indicates a positive development for Merck, likely to be viewed favorably by investors. The partnership and investment in a potentially pivotal trial demonstrate confidence in the program's success, which could have a positive impact on Merck's stock in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Moderna Inc's shares surged 8.96% to $112.26 following the announcement of a new trial for V940 in collaboration with Merck, highlighting investor confidence in the company's innovative therapy pipeline.
The significant rise in Moderna's stock price following the announcement of the new trial reflects strong investor confidence in the company's innovative therapy pipeline and its collaboration with Merck. The positive reception from analysts and the potential impact of the therapy on a growing incidence of cSCC contribute to the expectation of a positive short-term impact on Moderna's stock.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90